OBJECTIVE: To test the effect of the single nucleotide polymorphism -66 T>G (rs28357094) in the osteopontin gene (SPP1) on functional measures over 12 months in Duchenne muscular dystrophy (DMD). METHODS: This study was conducted on a cohort of ambulatory patients with DMD from a network of Italian neuromuscular centers, evaluated longitudinally with the north star ambulatory assessment (NSAA) and the 6-minute walk test (6MWT) at study entry and after 12 months. Genotype at rs28357094 was determined after completion of the clinical evaluations. Patients were stratified in 2 groups according to a dominant model (TT homozygotes vs TG heterozygotes and GG homozygotes) and clinical data were retrospectively compared between groups. RESULTS: Eighty patients were selected (age 4.1-19.3 years; mean 8.3 ± 2.7 SD). There were no differences in age or steroid treatment between the 2 subgroups. Paired t test showed a significant difference in both NSAA (p = 0.013) and 6MWT (p = 0.03) between baseline and follow-up after 12 months in patients with DMD carrying the G allele. The difference was not significant in the T subgroup. The analysis of covariance using age and baseline values as covariate and SPP1 genotype as fixed effect showed that these parameters are significantly correlated with the 12-month values. CONCLUSIONS: These data provide evidence of the role of SPP1 genotype as a disease modifier in DMD and support its relevance in the selection of homogeneous groups of patients for future clinical trials.
OBJECTIVE: To test the effect of the single nucleotide polymorphism -66 T>G (rs28357094) in the osteopontin gene (SPP1) on functional measures over 12 months in Duchenne muscular dystrophy (DMD). METHODS: This study was conducted on a cohort of ambulatory patients with DMD from a network of Italian neuromuscular centers, evaluated longitudinally with the north star ambulatory assessment (NSAA) and the 6-minute walk test (6MWT) at study entry and after 12 months. Genotype at rs28357094 was determined after completion of the clinical evaluations. Patients were stratified in 2 groups according to a dominant model (TT homozygotes vs TG heterozygotes and GG homozygotes) and clinical data were retrospectively compared between groups. RESULTS: Eighty patients were selected (age 4.1-19.3 years; mean 8.3 ± 2.7 SD). There were no differences in age or steroid treatment between the 2 subgroups. Paired t test showed a significant difference in both NSAA (p = 0.013) and 6MWT (p = 0.03) between baseline and follow-up after 12 months in patients with DMD carrying the G allele. The difference was not significant in the T subgroup. The analysis of covariance using age and baseline values as covariate and SPP1 genotype as fixed effect showed that these parameters are significantly correlated with the 12-month values. CONCLUSIONS: These data provide evidence of the role of SPP1 genotype as a disease modifier in DMD and support its relevance in the selection of homogeneous groups of patients for future clinical trials.
Authors: E Mazzone; G Vasco; M P Sormani; Y Torrente; A Berardinelli; S Messina; A D'Amico; L Doglio; L Politano; F Cavallaro; S Frosini; L Bello; S Bonfiglio; E Zucchini; R De Sanctis; M Scutifero; F Bianco; F Rossi; M C Motta; A Sacco; M A Donati; T Mongini; A Pini; R Battini; E Pegoraro; M Pane; S Gasperini; S Previtali; S Napolitano; D Martinelli; C Bruno; G Vita; G Comi; E Bertini; E Mercuri Journal: Neurology Date: 2011-07-06 Impact factor: 9.910
Authors: E Pegoraro; E P Hoffman; L Piva; B F Gavassini; S Cagnin; M Ermani; L Bello; G Soraru; B Pacchioni; M D Bonifati; G Lanfranchi; C Angelini; A Kesari; I Lee; H Gordish-Dressman; J M Devaney; C M McDonald Journal: Neurology Date: 2010-12-22 Impact factor: 9.910
Authors: Craig M McDonald; Erik K Henricson; Jay J Han; R Ted Abresch; Alina Nicorici; Gary L Elfring; Leone Atkinson; Allen Reha; Samit Hirawat; Langdon L Miller Journal: Muscle Nerve Date: 2010-04 Impact factor: 3.217
Authors: Kitipong Uaesoontrachoon; Hyun-Jin Yoo; Elizabeth M Tudor; Robert N Pike; Eleanor J Mackie; Charles N Pagel Journal: Int J Biochem Cell Biol Date: 2008-04-06 Impact factor: 5.085
Authors: E S Mazzone; S Messina; G Vasco; M Main; M Eagle; A D'Amico; L Doglio; L Politano; F Cavallaro; S Frosini; L Bello; F Magri; A Corlatti; E Zucchini; B Brancalion; F Rossi; M Ferretti; M G Motta; M R Cecio; A Berardinelli; P Alfieri; T Mongini; A Pini; G Astrea; R Battini; G Comi; E Pegoraro; L Morandi; M Pane; C Angelini; C Bruno; M Villanova; G Vita; M A Donati; E Bertini; E Mercuri Journal: Neuromuscul Disord Date: 2009-06-23 Impact factor: 4.296
Authors: Luca Bello; Heather Gordish-Dressman; Lauren P Morgenroth; Erik K Henricson; Tina Duong; Eric P Hoffman; Avital Cnaan; Craig M McDonald Journal: Neurology Date: 2015-08-26 Impact factor: 9.910
Authors: Annemieke Aartsma-Rus; Alessandra Ferlini; Elizabeth M McNally; Pietro Spitali; H Lee Sweeney Journal: Neuromuscul Disord Date: 2017-10-26 Impact factor: 4.296
Authors: Luca Bello; Kevin M Flanigan; Robert B Weiss; Pietro Spitali; Annemieke Aartsma-Rus; Francesco Muntoni; Irina Zaharieva; Alessandra Ferlini; Eugenio Mercuri; Sylvie Tuffery-Giraud; Mireille Claustres; Volker Straub; Hanns Lochmüller; Andrea Barp; Sara Vianello; Elena Pegoraro; Jaya Punetha; Heather Gordish-Dressman; Mamta Giri; Craig M McDonald; Eric P Hoffman Journal: Am J Hum Genet Date: 2016-10-13 Impact factor: 11.025
Authors: Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju Journal: ILAR J Date: 2014